Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm NALIRIFOX study in locally advanced pancreatic cancer
ChiCTR2600131901Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan, oxaliplatin, folinic acid and fluorouracil in pancreatic cancer (PC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Objective response rate and R0/R1 resection rate. Started Mar 2025; status: recruiting.
02
Drugs
nanoliposomal irinotecanoxaliplatinfolinic acidfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2600131901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131901.